Looking for real undervalued companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true provide proof with that statement!
What's going on you think?
Red to green
Paul knows exactly how this works. Stay tuned huge news could slap the %$^&$ out ya in the future!
The CISI study, underwritten by the National Biomedical Research Foundation, mapped the relationship between NIH-funded research and every new drug approved by the FDA between 2010 and 2016. The authors found that each of the 210 medicines approved for market came out of research supported by the NIH. Of the $100 billion it spent nationally during this period, more than half of it — $64 billion — ended up helping the development of 84 first-in-class drugs.
But the NIH doesn’t get to use the profits from these drugs to fund more research, the way it might under a model based on developing needed drugs and curing the sick, as opposed to serving Wall Street. Instead, publicly funded labs conduct years of basic research to get to a breakthrough, which is then snatched up, tweaked, and patented (privatized) by companies who turn around and reap billions with 1,000-times-cost mark-ups on drugs developed with taxpayer money.
https://other98.com/taxpayers-fund-pharma-research-development/
Historically, the largest government investments in basic drug discovery research have been made by the National Institutes of Health (NIH).
https://www.ncbi.nlm.nih.gov/books/NBK50972/#:~:text=Historically%2C%20the%20largest%20government%20investments,relatively%20high%2Drisk%20biologic%20projects.
https://www.otcmarkets.com/stock/CTYX/news/Connectyx-Announces-Grant-of-License-from-National-Institutes-of-Health-for-Use-of-Novel-Monoclonal-Antibody-to-Treat-Gl?id=277185
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma
Press Release | 10/16/2020
Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer.
The licensed patent rights include US Patent No. 10,548,987 issued February 02, 2020 (Patent Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-2015-0-US-03. “ANTIBODY - DRUG CONJUGATES FOR TARGETING CD56 - POSITIVE TUMORS.” The territory is worldwide.
While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.
Paul Michaels, Chairman and President of CTYX said, “We are pleased to have added this cutting-edge technology to our development portfolio. Pediatric Glioblastoma is one of the deadliest childhood diseases with an average survival rate of less than two years.”
Michaels concluded, “Recognizing the urgency for these patients and their families to find treatment options, our development plan anticipates being prepared for our First-in-Human clinical trial within 18 months, and our goal is to create a combined phase 1/phase 3 trial to accelerate development. We know these are extremely aggressive goals, but this is an extremely aggressive disease. At CTYX, we are building a pipeline of potential breakthrough medicines all of which can have an accelerated development pathway.”
About Pediatric Glioblastoma
Roughly 28,000 children are living with a primary brain tumor in the U.S. with approximately 3,700 new diagnoses each year. Brain and CNS cancers are the most prevalent of all childhood cancers. The five-year survival rate depends on the size, location, and makeup of the cancer; for the most aggressive Glioblastoma, it is less than two years.
About Connectyx Technologies Holdings Group, Inc. http://connectyx.com/
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is focused on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. At Connectyx, we envision a world where all patients have a therapeutic option.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CTYX is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Connectyx Technologies Holdings Group, Inc.
investorrelations@connectyx.com
Paul Michaels
561-418-7725
Nice bids in
Would like to see a .02 break
My God who still has .01s to sell unbelievable
$CTYX Board Member Michael Grace worked at Bristol Myers the parent company of Celgene
— Rise2ShineLife (@Rise2ShineLife) October 23, 2020
CTYX CEO Paul Michaels completed transactions that influenced Celgene Corp who is owned by Bristol Myers$EVK $SQBG $BGI $BPTH $ALGN $HLX $OPTN $BKSF $UONE $MARA $AMRS $HX $ANTE $MTSL $RIOT pic.twitter.com/hw0uo73Kmv
Who is paying for all that Paul has done thus far with out diluting the stock?
That is not true in every case in OTC
Don't play these games with me answer my question directly and stop deflecting and dancing around it.
How much do you think the relationships are worth this is business.
How much do you think her 20 years of relationships in the eye care space are worth as it pertains to CTYX and the retinal eye drop perspective license and patent?
They think it's a game http://www.pambisikirski.com/about
She like this post Paul posted on his linkedin
AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab
https://www.bloomberg.com/news/articles/2020-09-04/abbvie-inks-2-9-billion-cancer-deal-with-china-s-i-mab
https://www.linkedin.com/in/paul-m-michaels/
Now who is paying PAM BISIKIRSKI, our DIRECTOR OF COMMUNICATIONS
She doesn't come free what does she know already?
A communications and marketing leader, Pam Bisikirski guided the brand development of multiple healthcare optical centers including America’s Best Contacts & Eyeglasses and Eyeglass World while working at National Vision, Inc, (EYE) a $1.7 billion company. During her 20 year tenure at National Vision she managed the public relations for the organization as well as multi million dollar partnerships and endorsement programs.
Pam has also led communications as a consultant in the healthcare and retail spaces and is experienced with both start ups and rapidly expanding companies. Pam sat on the Board of Directors of Prevent Blindness Georgia for 6 years, the maximum allowed by the charitable foundation that is dedicated to preserving sight. She remains active in the organization.
https://connectyx.com/our-team/
Look what Henry found WOW another Patent and license in the cue!
$CTYX Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment of Retinal Degenerative Diseases in Humans https://t.co/RAS0PjDSBJ
— Henry (@HenryMuney) October 22, 2020
They pump nothing here they are successful in the private sector that's how they made there money I'm not even sure if they even understand how OTC works (the mindset of OTC).
Should be at .02+ by now
For who ever can use this info: To upload pics on IHUB click on settings then click on my pictures then click on choose file then upload. After the picture is uploaded copy and paste the link on the left hand side that says direct link. When you make a post on IHUB click on image and paste the link inside the [img][/img] and there you have it your picture will be uploaded when you post the post.
Same 911 trades on CTY* at the same time they hit here I thought that was strange and both had 2 in a row. Look at the trade data
Read the last sentence in this pic:
https://connectyx.com/wp-content/uploads/2020/06/Connectyx-Presentation-for-Investment-master_720x540_3.webm
We know Paul has ties to Asia/Japan
Now notice the territory is worldwide for the cancer drug:
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma
Boca Raton, FL (October 16, 2020) – Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody (mAB) in an antibody-drug conjugate to treat brain cancer.
The licensed patent rights include US Patent No. 10,548,987 issued February 02, 2020 (Patent Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-2015-0-US-03. “ANTIBODY - DRUG CONJUGATES FOR TARGETING CD56 - POSITIVE TUMORS.” The territory is worldwide.
Stay tuned!
A milestone payment agreement for the cancer drug could shock OTC remember Paul is going all the way with it. The rabies drug looks like they are going to sell the voucher.
Paul posted this article on his https://www.linkedin.com/in/paul-m-michaels/
AbbVie to develop and sell China-based I-Mab's cancer drug
By Reuters Staff
(Reuters) - U.S. drug maker AbbVie Inc will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab’s cancer drug, the companies said on Friday.
The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark’s biotech firm Genmab AS to co-develop and market cancer drugs.
AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China.
https://www.reuters.com/article/us-imab-abbvie-idUSKBN25V1L9
Another Milestone payment scenerio:
Takeda, Evox in $882-M Deal for Rare Diseases
April 2, 2020
Takeda has formed a licensing pact with Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, in a deal worth up to $882 million ($44 million upfront) for the development of protein-replacement and mRNA therapies.
Under the agreement, Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding. In total, Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda. Evox will also receive tiered royalties on net sales of each product.
https://dcatvci.org/pharma-news/6430-takeda-evox-in-882-m-deal-for-rare-diseases
CTYX DD:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156063993
Stay tuned one day news similar to this could hit.
First that link is intended for Tropical Diseases
What is tropical disease?
Tropical disease, any disease that is indigenous to tropical or subtropical areas of the world or that occurs principally in those areas. Examples of tropical diseases include malaria, cholera, Chagas disease, yellow fever, and dengue
Second CTYX is in the Orphan Drug/Rare Disease space
Orphan Drug Designation Awardees are Granted the Following Benefits from the FDA:
Tax credits of 50% off the clinical drug testing cost awarded upon approval
Eligibility for market exclusivity for 7 years post approval
Waiver of new drug application (NDA)/ biologics license application
(BLA) application fee (approximately $2.2 million value)
https://www.americangene.com/blog/benefits-of-fda-orphan-drug-designation-what-you-need-to-know/
https://www.fda.gov/media/113889/download
Probably you know who from this board lol
Can't wait until the voucher sold news hits this is a must read for new shareholders:
Boca Raton, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies. IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines.
IMT504 has been granted orphan drug designation in the US, which provides significant benefits including tax credits, market exclusivity and waiver of certain FDA fees. Rabies is one of only 14 diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria.
Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, and their value has increased. In 2016–2018, the value of a voucher ranged from $125 million to $200 million.
Paul M. Michaels, Connectyx CEO said. “Since 2001, over a million people worldwide have died from rabies. While the number is fortunately small in the U.S., in much of the world it is still a significant problem with no treatment options for patients who have progressed to late-stage rabies disease. Our goal is to be in the clinic by Q1 2022. As a result of the near 100% fatality rate in late-stage rabies, we anticipate being able to implement an adaptive clinical trial strategy that could lead to rapid FDA approval.”
https://www.globenewswire.com/news-release/2020/10/09/2106348/0/en/Connectyx-Technologies-Holdings-Group-Inc-Announces-Definitive-Agreement-with-Mid-Atlantic-BioTherapeutics-Inc-for-Treatment-of-Symptomatic-Rabies.html
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada.
The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration (FDA) of ERVEBO®, a vaccine developed by the Company’s licensee, Merck, for the prevention of the Zaire Ebola virus disease. Under the terms of the original license agreement Lumos Pharma is entitled to retain 60% of the value of the PRV. Based upon an agreed valuation of $100 million Merck will pay Lumos $60 million. The transaction remains subject to customary closing conditions, including anti-trust review.
“We are pleased to announce the sale of the PRV, which will provide an important source of non-dilutive capital to fund additional investment in our pipeline and the evaluation of other assets for potential acquisitions or partnerships. These efforts will be critical to our growth over the coming year, and we are committed to our strategic priority of becoming leaders in the rare and ultra-rare disease space,” said Rick Hawkins, Chairman, CEO and President. “Additionally, we are looking forward to initiating our Phase 2b trial of our lead candidate LUM-201 in patients with Pediatric Growth Hormone Deficiency, or PGHD, prior to the end of 2020. We believe we have the opportunity to greatly improve the standard of care for patients impacted by this disease. If approved, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment.”
Jefferies LLC. acted as exclusive financial advisor to Lumos Pharma, Inc. on this transaction.
Financial Guidance Update Related to PRV Sale
The total valuation of the PRV in the transaction was $100 million. Lumos Pharma will receive approximately $60 million which represents the Company’s 60% interest in the total value of the PRV. The $60 million will be received in two non-contingent payments, $34 million in 2020 and $26 million in the first quarter of 2021. The non-dilutive funds from this transaction will provide additional capital to support the expansion of its pipeline through the in-licensing or acquisition of another novel therapeutic candidate for those suffering from rare diseases. These funds are in addition to the Company’s cash position as of March 31, 2020 which was anticipated to be sufficient to support the Company’s current operations through the Phase 2b clinical trial read-out.
https://www.globenewswire.com/news-release/2020/07/27/2068182/0/en/Lumos-Pharma-Announces-Sale-of-Priority-Review-Voucher.html#:~:text=Lumos%20Pharma%20will%20receive%20approximately,the%20first%20quarter%20of%202021
Please send it
$CTYX has an agreement with the National Cancer Institute learn about it! https://t.co/eM6Yo2ApxYhttps://t.co/5iPia82CCo #bigpharma #raredisease @pfizer @GileadSciences @Merck @TakedaPharma$BSTC $LQDA $ATHA $ENDP $ATHE $AVXL $COGT$TARA $CTXR $CBIO $AERI $KLDO $RAPT $CRDF https://t.co/ewV1YtVbtd pic.twitter.com/nkDqXKOzhk
— Rise2ShineLife (@Rise2ShineLife) October 20, 2020
Mods please stickie post #25125
DD on why this is not a game and a likely scenario that could happen here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156063993
Wish they could redo the PR stating the revenues of the company
Hi Shanak good to see you
$CTYX Board member MICHAEL GRACE
— Rise2ShineLife (@Rise2ShineLife) June 9, 2020
30 years of Exec and Tech work at Schering-Plough Bristol Myers Squibb, NPS Pharma. He has contributed to or personally led the development to commercial approval of 9 drugs including PEG-Intron™ Orencia™ Nulojix™ Yervoy™ Gattex™ Natpara™ https://t.co/szgFktsdkf pic.twitter.com/iCkheOhUdU
$CTYX Board Member Ronald Bordens PH.D. is an executive scientist with over 40 years of successful experience. His pharmaceutical industry experience includes drug discovery and drug development.
— Rise2ShineLife (@Rise2ShineLife) June 4, 2020
26-year career at Schering-Plough which is now Merck & Co https://t.co/gKth6cuTpu https://t.co/zwNag3DHGJ pic.twitter.com/BQKjQ5BqDg
$CTYX entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute!https://t.co/pYbdry8R4K$BSTC $LQDA $ATHA $ENDP $ATHE $AVXL $COGT$TARA $CTXR $CBIO $AERI $KLDO $RAPT $CRDF$VIE $SURF $BCLI $SELB $RCUS $BSTC $LQDA pic.twitter.com/2x88bCR5Vd
— Rise2ShineLife (@Rise2ShineLife) October 19, 2020
Thanks Eagle1!
Been on vacation and haven't looked at this board in about a week so I'm just now seeing the John Benard post so I just deleted the stickie in reference to him.
I still have my shares also hmu on twitter been trying to reach you.
Article about Tesla's battery day:
Musk himself acknowledged, as he often does, the difficulties that come with “building the machine that builds the machine,” a nod to the fact that Tesla will have to create a bunch of battery bots to make it happen. He says he expects it to be “about a year” before Tesla’s new battery factory is producing cells at its full capacity—but even that is a remarkably fast turnaround by the industry’s standards
https://www.wired.com/story/where-was-the-battery-at-teslas-battery-day/